Prognostic factors for PFS and OS after acquisition of del(17p). Presence of ≥ 40% plasma cells (PCs) with del(17p) predicted shorter PFS, and high PC proliferative rate predicted shorter OS. (A) The median PFS in patients with del(17p) involving ≥ 40% PCs was 3.5 months (95% CI, 1.9-5.7) and in those with < 40% PCs, it was 11.3 months (95% CI, 4.4-15.6) (P = .008). (B) The median OS from detection of del(17p) was 8.9 months (95% CI, 4.9-17.1) among those with high PC proliferation rate and was 35.6 months (95% CI, 18.2- 47.5) among those with low PC proliferation rate (P = .003).